Systemic Therapy Selection and FDA-Approved Treatment

Dr. Bouberhan inquires about systemic therapy selection for patients with advanced or metastatic PEComas unsuitable for surgical resection. Dr. Choy explains that treatment approaches transformed approximately 2 years ago with FDA approval of nab-sirolimus specifically for PEComa treatment, fundamentally changing therapeutic paradigms.

The molecular foundation stems from TSC1/TSC2 loss in approximately half of PEComas, creating crosstalk disruption with the mTOR (mechanistic target of rapamycin) pathway. This biological understanding prompted decades of investigation using mTOR inhibitory drugs including sirolimus and temsirolimus. However, oral sirolimus presented significant challenges with unpredictable absorption, variable blood levels, and dosing difficulties that complicated optimal therapeutic delivery.

The breakthrough came through nab-sirolimus development, utilizing nanoparticle albumin-bound formulation to overcome absorption variability. The AMPECT phase 2 trial demonstrated remarkable efficacy in patients with advanced PEComas, achieving 39% response rates (tumor shrinkage or prolonged stable disease) with 10.6-month progression-free survival and 40.8-month overall survival. These outcomes substantially exceeded historical results with oral sirolimus alone.

Notably, molecular subtype strongly predicted treatment response. Patients with TSC2 mutations achieved nearly 90% response rates, whereas those with non-TSC2 mutations demonstrated only 13% response rates. Despite being a single-arm phase 2 study rather than randomized controlled trial, the profound survival prolongation convinced FDA approval for commercial use based on exceptional efficacy signals.

Dr. Choy emphasizes that complete surgical resection remains the gold standard for cure, with nab-sirolimus reserved for metastatic disease or selected locally advanced cases. For locally advanced disease, he considers patients potentially curable through tumor shrinkage strategies using neoadjuvant nab-sirolimus or preoperative radiation to render tumors operable. The ultimate goal involves achieving complete surgical resection, as cure rarely occurs without surgical intervention even with effective systemic therapy.